Data / Public companies / SIC 2836: Biological products, (no diagnostic substances) / X4 Pharmaceuticals, Inc
X4 Pharmaceuticals, Inc: revenue, net income and total assets from its latest annual report
Updated March 17, 2026. Source: SEC Financial Statement Data Sets, filing 0001501697-26-000018.
X4 Pharmaceuticals, Inc reported revenue of $35.1 million, a net loss of $79.2 million and total assets of $290.5 million for the fiscal year ended December 31, 2025, in its annual report (10-K) filed with the SEC on March 17, 2026. It ranks 48th by revenue of 89 companies in SIC 2836, biological products, (no diagnostic substances).
The request: Watch X4 Pharmaceuticals, Inc (CIK 1501697): each new SEC filing, with revenue and net income. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the annual reports that companies file with the SEC, and this page is that reading. Ask for the companies of an industry, state or city with their website, number of employees and funding added from the web, and each new annual report arrives in your sheet, CRM, Slack or agent as the SEC posts it.
- SEC central index key (CIK)
- 1501697
- Industry
- SIC 2836, Biological products, (no diagnostic substances)
- Business address (city and state)
- Boston, Massachusetts
- Incorporated in
- Delaware
- Filer category
- Non-accelerated filer
- Fiscal year ends
- December 31
- Latest annual report
- 10-K filed March 17, 2026
- Annual and quarterly reports in the data
- 1 annual, 4 quarterly
Financials for the fiscal year ended December 31, 2025
As filed, in US dollars. The prior year value is the comparison column in the same report.
| Item | This year | Prior year | Change | Source |
|---|---|---|---|---|
| Revenue | $35,113,000 | $2,557,000 | 1,273.2% | sec.gov |
| Operating income | $-86,883,000 | Not listed | Not listed | sec.gov |
| Net income | $-79,199,000 | $-37,450,000 | -111.5% | sec.gov |
| Total assets | $290,461,000 | $146,447,000 | 98.3% | sec.gov |
| Total liabilities | $104,171,000 | Not listed | Not listed | sec.gov |
| Stockholders' equity | $186,290,000 | Not listed | Not listed | sec.gov |
| Cash and cash equivalents | $217,049,000 | Not listed | Not listed | sec.gov |
How it compares
- Net margin (net income over revenue)
- -225.6%
- Revenue change on the prior year
- 1273.2%
- Revenue rank in SIC 2836
- 48th of 89
- Revenue rank in Massachusetts
- 142nd of 185
- Revenue rank among all companies in the data
- 3,216th of 4,486
Companies next to it by revenue in SIC 2836
Biological products, (no diagnostic substances), from the same data.
| Company | Business address | Revenue | Net income | Total assets | Revenue change |
|---|---|---|---|---|---|
| Voyager Therapeutics, Inc. | Lexington, MA | $40.4 million | $-119,721,000 | $252.3 million | -49.5% |
| Sangamo Therapeutics, Inc | Richmond, CA | $39.6 million | $-122,932,000 | $59.7 million | -31.6% |
| Kymera Therapeutics, Inc. | Watertown, MA | $39.2 million | $-311,351,000 | $1.74 billion | -16.7% |
| C4 Therapeutics, Inc. | Watertown, MA | $35.9 million | $-104,994,000 | $359.1 million | 1% |
| Precision Biosciences Inc | Durham, NC | $34.3 million | $-45,724,000 | $154.4 million | -50.1% |
| Scilex Holding Co | Palo Alto, CA | $30.3 million | $-374,053,000 | $365 million | -46.5% |
| Metagenomi Therapeutics, Inc. | Emeryville, CA | $25.2 million | $-87,868,000 | $221.1 million | -51.8% |
| Arcellx, Inc. | Redwood City, CA | $22.3 million | $-228,934,000 | $604 million | -79.4% |
Public data from the US Securities and Exchange Commission. Companies are the registrants whose latest annual report (form 10-K, 20-F or 40-F) is in the SEC Financial Statement Data Sets for 2025 Q3 to 2026 Q3, filed through September 30, 2026. Figures are for the whole fiscal year of that report, in US dollars, as the company filed them in XBRL: SpecStream does not adjust them. The SEC does not guarantee the data sets, and they do not replace the filings. Revenue is the revenue tag the company used; banks and funds often use none. Combined totals add each company once and can include a parent and its subsidiary that both file. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.